BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 2834409)

  • 1. Maintenance of the ratio of bioactive to immunoreactive follicle-stimulating hormone in normal men during chronic luteinizing hormone-releasing hormone agonist administration.
    Pavlou SN; Dahl KD; Wakefield G; Rivier J; Vale W; Hsueh AJ; Lindner J
    J Clin Endocrinol Metab; 1988 May; 66(5):1005-9. PubMed ID: 2834409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mode of suppression of pituitary and gonadal function after acute or prolonged administration of a luteinizing hormone-releasing hormone antagonist in normal men.
    Pavlou SN; Wakefield G; Schlechter NL; Lindner J; Souza KH; Kamilaris TC; Konidaris S; Rivier JE; Vale WW; Toglia M
    J Clin Endocrinol Metab; 1989 Feb; 68(2):446-54. PubMed ID: 2537334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gonadotropin and steroid secretory patterns during chronic treatment with a luteinizing hormone-releasing hormone agonist analog in men.
    Evans RM; Doelle GC; Alexander AN; Uderman HD; Rabin D
    J Clin Endocrinol Metab; 1984 May; 58(5):862-7. PubMed ID: 6423661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The luteinizing hormone-releasing hormone (LHRH) agonist [D-Trp6-Pro9-NEt]LHRH increased rather than lowered LH and alpha-subunit levels in a patient with an LH-secreting pituitary tumor.
    Roman SH; Goldstein M; Kourides IA; Comite F; Bardin CW; Krieger DT
    J Clin Endocrinol Metab; 1984 Feb; 58(2):313-9. PubMed ID: 6198331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gonadotropin and alpha-subunit responses to chronic gonadotropin-releasing hormone analog administration in patients with glycoprotein hormone-secreting pituitary tumors.
    Klibanski A; Jameson JL; Biller BM; Crowley WF; Zervas NT; Rivier J; Vale WW; Bikkal H
    J Clin Endocrinol Metab; 1989 Jan; 68(1):81-6. PubMed ID: 2535852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence of concordant luteinizing hormone (LH), testosterone, and alpha-subunit pulses after LH-releasing hormone antagonist administration in normal men.
    Pavlou SN; Veldhuis JD; Lindner J; Souza KH; Urban RJ; Rivier JE; Vale WW; Stallard DJ
    J Clin Endocrinol Metab; 1990 May; 70(5):1472-8. PubMed ID: 2110578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormonal effects of gonadotropin-releasing hormone (GnRH) agonist in the human male. III. Effects of long term combined treatment with GnRH agonist and androgen.
    Bhasin S; Heber D; Steiner BS; Handelsman DJ; Swerdloff RS
    J Clin Endocrinol Metab; 1985 May; 60(5):998-1003. PubMed ID: 3920237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intermittent long-term administration of a potent gonadotropin-releasing hormone agonist in normal men.
    Doelle G; Linde R; Alexander N; Kirchner F; Vale W; Rivier J; Rabin D
    Int J Fertil; 1982; 27(4):234-7. PubMed ID: 6131043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the luteinizing hormone-releasing hormone (LHRH) analog D-Trp6-Pro9-NEt-LHRH on the pituitary-gonadal axis of prepubertal rhesus monkeys.
    Cassorla F; Renquist D; Barnard D; Munabi AK; Cutler GB; Loriaux DL
    Biol Reprod; 1984 Jun; 30(5):1130-4. PubMed ID: 6428479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gonadotropin and alpha-subunit secretion during long term pituitary suppression by D-Trp6-luteinizing hormone-releasing hormone microcapsules as treatment of precocious puberty.
    Lahlou N; Roger M; Chaussain JL; Feinstein MC; Sultan C; Toublanc JE; Schally AV; Scholler R
    J Clin Endocrinol Metab; 1987 Nov; 65(5):946-53. PubMed ID: 2959680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate.
    Tom L; Bhasin S; Salameh W; Steiner B; Peterson M; Sokol RZ; Rivier J; Vale W; Swerdloff RS
    J Clin Endocrinol Metab; 1992 Aug; 75(2):476-83. PubMed ID: 1639948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single subcutaneous doses of a luteinizing hormone-releasing hormone antagonist suppress serum gonadotropin and testosterone levels in normal men.
    Pavlou SN; Debold CR; Island DP; Wakefield G; Rivier J; Vale W; Rabin D
    J Clin Endocrinol Metab; 1986 Aug; 63(2):303-8. PubMed ID: 3088019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of pituitary-testicular axis suppression in utero and during the early neonatal period with a long-acting luteinizing hormone-releasing hormone analog on genital development, somatic growth, and bone density in male cynomolgus monkeys in the first 6 months of life.
    Liu L; Cristiano AM; Southers JL; Reynolds JC; Bacher J; Brown G; Gilley RM; Tice TR; Banks SM; Loriaux LD
    J Clin Endocrinol Metab; 1991 Nov; 73(5):1038-43. PubMed ID: 1939516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneity of sperm density profiles following 16-week therapy with continuous infusion of high-dose LHRH analog plus testosterone.
    Pavlou SN; Interlandi JW; Wakefield G; Rivier J; Vale W; Rabin D
    J Androl; 1986; 7(4):228-33. PubMed ID: 3528106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of deslorelin dose in the treatment of central precocious puberty.
    Pescovitz OH; Barnes KM; Cutler GB
    J Clin Endocrinol Metab; 1991 Jan; 72(1):60-4. PubMed ID: 1898743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differing responses of plasma bioactive and immunoreactive follicle-stimulating hormone and luteinizing hormone to gonadotropin-releasing hormone antagonist and agonist treatments in postmenopausal women.
    Matikainen T; Ding YQ; Vergara M; Huhtaniemi I; Couzinet B; Schaison G
    J Clin Endocrinol Metab; 1992 Sep; 75(3):820-5. PubMed ID: 1517372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long term treatment of male and female precocious puberty by periodic administration of a long-acting preparation of D-Trp6-luteinizing hormone-releasing hormone microcapsules.
    Roger M; Chaussain JL; Berlier P; Bost M; Canlorbe P; Colle M; Francois R; Garandeau P; Lahlou N; Morel Y
    J Clin Endocrinol Metab; 1986 Apr; 62(4):670-7. PubMed ID: 2936759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ratios of serum bioactive/immunoreactive luteinizing hormone and follicle-stimulating hormone in various clinical conditions with increased and decreased gonadotropin secretion: reevaluation by a highly sensitive immunometric assay.
    Jaakkola T; Ding YQ; Kellokumpu-Lehtinen P; Valavaara R; Martikainen H; Tapanainen J; Rönnberg L; Huhtaniemi I
    J Clin Endocrinol Metab; 1990 Jun; 70(6):1496-505. PubMed ID: 2140831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The biologic activity of a potent analogue of gonadotropin-releasing hormone in normal and hypogonadotropic men.
    Crowley WF; Beitins IZ; Vale W; Kliman B; Rivier J; Rivier C; McArthur JW
    N Engl J Med; 1980 May; 302(19):1052-7. PubMed ID: 6767977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of active and passive immunization with luteinizing hormone-releasing hormone on serum luteinizing hormone and follicle-stimulating hormone levels and the ultrastructure of the pituitary gonadotrophs in castrated male rats.
    Arimura A; Shino M; de la Cruz KG; Rennels EG; Schally AV
    Endocrinology; 1976 Jul; 99(1):291-303. PubMed ID: 780100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.